Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by ANTIPODES PARTNERS Ltd

ANTIPODES PARTNERS Ltd grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 19.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 159,554 shares of the biopharmaceutical company's stock after acquiring an additional 25,795 shares during the period. Alnylam Pharmaceuticals comprises 1.3% of ANTIPODES PARTNERS Ltd's holdings, making the stock its 24th biggest position. ANTIPODES PARTNERS Ltd owned about 0.12% of Alnylam Pharmaceuticals worth $43,086,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Whipplewood Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 71 shares during the period. Bessemer Group Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 69 shares during the period. Park Square Financial Group LLC acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth $28,000. Colonial Trust Co SC acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth $35,000. Finally, Washington Trust Advisors Inc. raised its position in Alnylam Pharmaceuticals by 53.5% during the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock worth $47,000 after acquiring an additional 61 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ALNY has been the subject of a number of research analyst reports. Jefferies Financial Group upped their price objective on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a "buy" rating in a research report on Monday, July 7th. Bank of America upped their price objective on shares of Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the stock a "buy" rating in a research report on Friday, July 11th. Morgan Stanley reduced their price objective on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating for the company in a research report on Friday, April 11th. Redburn Atlantic initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, March 31st. They set a "buy" rating and a $353.00 price objective for the company. Finally, UBS Group upped their price objective on shares of Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and twenty-three have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $347.75.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 19,297 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total value of $5,904,882.00. Following the sale, the chief executive officer owned 48,948 shares of the company's stock, valued at $14,978,088. This trade represents a 28.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Stock Up 0.2%

Shares of NASDAQ ALNY traded up $0.81 during midday trading on Friday, hitting $328.81. The company's stock had a trading volume of 666,674 shares, compared to its average volume of 911,887. The business's fifty day simple moving average is $311.56 and its two-hundred day simple moving average is $274.67. The company has a debt-to-equity ratio of 8.88, a current ratio of 3.04 and a quick ratio of 2.98. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $333.70. The firm has a market capitalization of $42.87 billion, a price-to-earnings ratio of -157.33 and a beta of 0.23.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The business had revenue of $594.19 million during the quarter, compared to analysts' expectations of $584.32 million. Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The company's revenue for the quarter was up 20.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.16) EPS. On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.